HomePfizer is Reportedly Lobbying Against Key Amendments to the False Claims Act

Pfizer is Reportedly Lobbying Against Key Amendments to the False Claims Act

Geoff Schweller
Published On: November 30th, 2021Categories: False Claims/Qui Tam, Whistleblower News and Qui Tam Blog

As previously reported, large pharmaceutical corporations are aggressively lobbying against amendments to the False Claims Act which strengthen the law’s capability to hold companies accountable for fraud. New reporting details that Pfizer is among the companies that has tried to block the False Claims Amendment Act of 2021 from passing.

The False Claims Act has been described by the U.S. Assistant Attorney General as “the most powerful tool the American people have to protect the government from fraud.” The qui tam provisions of the law have empowered whistleblowers to expose fraud and allowed the government to recover over $64 billion.

Like many other pharmaceutical companies, Pfizer has paid hefty fines for violations of the False Claims Act. In 2009, Pfizer “agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products,” according to the DOJ. This record settlement stemmed from a lawsuit brought against Pfizer by six whistleblowers.

In recent years, the False Claims Act has been weakened by court decisions which have altered the definition of “materiality.” In short, under recent court interpretations, False Claims Act suits can be dismissed if the government continued to pay the fraudulent contract despite someone, somewhere in the government, having knowledge of the false claims submitted by the organization.

The False Claims Amendments Act was introduced by a bipartisan group of Senators led by Senator Chuck Grassley (R-IA) on July 26. The Act primarily clarifies the definition of “materiality” to ensure that corporations are still held liable for the fraud they commit. The Act is widely supported by whistleblower advocacy groups, including the National Whistleblower Center (NWC) and the Project on Government Oversight (POGO).

While whistleblower and anti-fraud advocates support the amendments, pharmaceutical companies have aggressively lobbied against the bill. According to recent reporting by The Intercept, “[m]any of the companies engaged in the lobbying fight have chosen to conceal their efforts through undisclosed third-party groups such as the U.S. Chamber of Commerce, which has made the Grassley bill one of its primary targets for defeat. The chamber does not disclose its membership or which corporations direct its advocacy, but previous reporting suggests companies such as Halliburton, Lockheed Martin, and JPMorgan Chase, among others that have faced False Claims Act violations in the past.”

The Intercept further reports that “[t]he known corporate interests lobbying on the Grassley bill include Pfizer, Amgen, AstraZeneca, Merck, and Genentech. These companies listed the legislation on lobbying disclosures. All five have paid nine-figure settlements over health care fraud brought to light through the False Claims Act.”

“This is a very concerted lobbying effort that really took our supporters on Capitol Hill by surprise,” KKC founding partner Stephen M. Kohn told The Intercept. “Drug companies are notorious for paying kickbacks, giving benefits in exchange for a competitive advantage. Drug companies and health care firms are about 80 percent of the False Claim[s] Act recoveries for a reason.”

Despite the aggressive corporate lobbying, on October 28, the Senate Judiciary Committee voted to advance the bill. A full Senate vote on the bill has yet to be announced.

Latest News & Insights

  • May 20, 2022

    On May 25, leading whistleblower groups from both sides of the Atlantic are coming together for a free public event highlighting whistleblower developments in both the United States and the United Kingdom. The event, which is both ...

  • May 19, 2022

    On May 19, the U.S. Securities and Exchange Commission (SEC) issued a whistleblower award to an individual who voluntarily provided the agency with original information that led to a successful enforcement action. Through the SEC ...

  • May 17, 2022

    On May 16, leading whistleblower attorney Stephen M. Kohn of Kohn, Kohn & Colapinto gave a keynote address at a U.S. Department of State International Visitor Leadership Program (IVLP) event. The event was part of a program en ...

  • May 12, 2022

    On May 12, the U.S. Internal Revenue Service (IRS) announced that John W. Hinman will serve as the Director of the IRS Whistleblower Office. Hinman will oversee the agency’s highly successful whistleblower award program. Since 200 ...

Subscribe for News & Resources

Our content is crafted and curated by the partners and associates at KKC.